Article Text


FRI0042 Anakinra improves functional status in patients with rheumatoid arthritis using methotrexate
  1. SB Cohen1,
  2. JM Woolley2,
  3. WW Chan2
  1. 1Department of Rheumatology, St. Paul Medical Center, Dallas, USA
  2. 2Amgen Inc., Thousand Oaks, USA


Objectives To evaluate the effect of anakinra, with respect to dose response and speed of effect, on the functional status of subjects with rheumatoid arthritis (RA) who were using methotrexate.

Methods In a large, multidose, placebo-controlled study of anakinra, 419 patients with active RA were randomised to receive, in addition to Methotrexate (MTX), either. 04 to 2.0 mg/kg of anakinra (daily SC injection) or placebo. Functional status was evaluated at baseline and after 4, 8, 12, 16, 20, and 24 weeks of therapy using the Health Assessment Questionnaire (HAQ). Comparisons between MTX alone and anakinra + MTX were analysed using change scores from baseline.

Results Patients receiving higher doses of anakinra experienced rapid and sizeable improvements in their HAQ scores. In percentage terms, HAQ scores improved more than 35 percent over baseline for the two highest doses (data not shown). These improvements occurred rapidly, were related to dose (p = 0.0014), and by week 4 the two highest doses were statistically significantly superior to placebo.

Abstract FRI0042 Table 1

Mean change in HAQ from baseline by dose of anakinra (+MTX) over time

Conclusion In patients with active disease despite methotrexate therapy, the addition of anakinra led to rapid and clinically important improvements in functional status. These improvements were related to dose. Anakinra improves functional status in subjects with rheumatoid arthritis.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.